MicroRNAs in the skeleton: cell-restricted or potent intercellular communicators?

Arch Biochem Biophys

Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands. Electronic address:

Published: November 2014

MicroRNAs (miRNAs) play a fundamental role in cell proliferation, differentiation and apoptosis and have been associated with many diseases and physiological states. Within the skeleton, both the bone forming cells, osteoblasts, and the bone degrading cells, osteoclasts, are mostly being stimulated by miRNAs through downregulation of inhibitors of bone cell differentiation. Besides miRNAs affecting master genes of bone cell differentiation and function in a cell-restricted manner, evidence is gathering that miRNAs are excreted into the local environment but also into the circulation, implicating a role for miRNAs in nearby or even distant target cells. In this review, the most recent novel miRNAs implicated in bone cell differentiation regulation will be described but also their potential paracrine or endocrine role, thus reinforcing the concept that miRNAs may function as powerful communicators between cell types or tissues.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.abb.2014.04.016DOI Listing

Publication Analysis

Top Keywords

bone cell
12
cell differentiation
12
mirnas
7
cell
5
bone
5
micrornas skeleton
4
skeleton cell-restricted
4
cell-restricted potent
4
potent intercellular
4
intercellular communicators?
4

Similar Publications

Extracellular vesicles: essential agents in critical bone defect repair and therapeutic enhancement.

Mol Biol Rep

January 2025

Pediatric Cell, and Gene Therapy Research Center Gene, Cell and Tissue Research Institute, Tehran University of Medical Sciences, Tehran, Iran.

Bone serves as a fundamental structural component in the body, playing pivotal roles in support, protection, mineral supply, and hormonal regulation. However, critical-sized bone injuries have become increasingly prevalent, necessitating extensive medical interventions due to limitations in the body's capacity for self-repair. Traditional approaches, such as autografts, allografts, and xenografts, have yielded unsatisfactory results.

View Article and Find Full Text PDF

Knockdown of miR-182 changes the sensitivity of triple-negative breast cancer cells to cisplatin.

Nucleosides Nucleotides Nucleic Acids

January 2025

Division of Hematology, Department of Internal Medicine, Medical Faculty, Tekirdağ Namık Kemal University, Tekirdağ, Turkey.

Breast cancer is the most common malignancy that affects women. MicroRNAs (miRNAs) play an essential role in cancer therapy and regulate many biological processes such as cisplatin resistance. The study's objective was to determine whether miR-182 dysregulation was the cause of cisplatin resistance in TNBC cell line MDA-MB-231.

View Article and Find Full Text PDF

Background: Denosumab represents a valuable treatment option for unresectable giant cell tumors of the bone (GCTBs). However, no standardized protocols exist determining the length of administration, with few studies having been published on patients who reached the end of treatment.

Aims: To analyze the outcomes of patients diagnosed with GCTB and who had finished single treatment with denosumab.

View Article and Find Full Text PDF

Dasatinib and Quercetin Limit Gingival Senescence, Inflammation, and Bone Loss.

J Dent Res

January 2025

Department of Periodontics, School of Dental Medicine, University of Pennsylvania, Philadelphia, PA, USA.

Cellular senescence has emerged as one of the central hallmarks of aging and drivers of chronic comorbidities, including periodontal diseases. Senescence can also occur in younger tissues and instigate metabolic alterations and dysfunction, culminating in accelerated aging and pathological consequences. Senotherapeutics, such as the combination of dasatinib and quercetin (DQ), are being increasingly used to improve the clinical outcomes of chronic disorders and promote a healthy life span through the reduction of senescent cell burden and senescence-associated secretory phenotype (SASP).

View Article and Find Full Text PDF

Background/objectives: Acute myeloid leukemia (AML) is an aggressive neoplasm. Although most patients respond to induction therapy, they commonly relapse due to recurrent disease in the bone marrow microenvironment (BMME). So, the disruption of the BMME, releasing tumor cells into the peripheral circulation, has therapeutic potential.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!